Estrogen in cardiovascular disease

Current Opinion in Lipidology

Volumn 15, Issue 5, 2004, Pages 589-593

  Zhu, Weifei ^a   Everson, William V ^a   Smart, Eric J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Atherosclerosis; Endothelial nitric oxide synthase; Estrogen; Hormone replacement therapy; Menopause

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE SYNTHASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; ENDOTHELIUM; ESTROGEN THERAPY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MONOCYTE; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPOPROTEINS; MACROPHAGES; MONOCYTES;

EID: 5044235308     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200410000-00014     Document Type: Review

References (55)

1. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002; 53:550-557.
2. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340:1801-1811.
3. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-1037.
4. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. N Engl J Med 1991; 325:756-762.
5. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288:49-57.
6. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349:535-545.
7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1771. This report summarizes the results leading to termination of the conjugated equine estrogen alone arm of the Women's Health Initiative due to negative effects.
9. Knopp RH, Aikawa K, Knopp EA. Estrogen therapies, lipids, and the heart disease prevention controversy. Curr Cardiol Rep 2003; 5:477-482. This interesting article summarizes some of the potential reasons the WHI trial failed to show positive effects, and outlines further studies in this area.
10. Subbiah MT. Cardiovascular risk associated with hormone replacement therapy: some critical questions about the type of estrogen used in most clinical trials. Atherosclerosis 2004; 173:373-374. This intriguing comment identifies some critical questions that remain to be addressed in future clinical trials on postmenopausal hormone replacement therapy.
11. Wakatsuki A, Ikenoue N, Shinohara K, et al. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterios Thromb Vasc Biol 2004; 24:571-576. This paper provides data indicating that lower doses of conjugated estrogens do not increase known cardiovascular risk factors which are elevated when the standard therapeutic dose is given.
12. Wakatsuki A, Okatani Y, Ikenoue N, et al. Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2003; 108:808-813. This paper provides data indicating that lower doses of conjugated estrogens do not increase known cardiovascular risk factors which are elevated when the standard therapeutic dose is given.
13. Ossewaarde ME, Dallinga-Thie GM, Bots ML, et al. Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial. Eur J Clin Invest 2003; 33:376-382. This paper provides data indicating that lower doses of conjugated estrogens do not increase known cardiovascular risk factors which are elevated when the standard therapeutic dose is given.
14. Mercuro G, Vitale C, Fini M, et al. Lipid profile and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial. Int J Cardiol 2003; 89:257-265. This paper provides data indicating that lower doses of conjugated estrogens do not increase known cardiovascular risk factors which are elevated when the standard therapeutic dose is given.
15. Rontu R, Solakivi T, Teisala K, et al. Impact of long-term hormone replacement therapy on in vivo and in vitro markers of lipid oxidation. Free Radic Res 2004; 38:129-137.
16. Abplanalp W, Scheiber MD, Moon K, et al. Evidence for the role of high density lipoproteins in mediating the antioxidant effect of estrogens. Eur J Endocrinol 2000; 142:79-83.
17. Primm TP, Gilbert HF. Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum. J Biol Chem 2001; 276:281-286.
18. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
19. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109:II27-II33.
20. Razandi M, Oh P, Pedram A, et al. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 2002; 16:100-115.
21. Mendelsohn ME. Genomic and nongenomic effects of estrogen in vasculature. Am J Cardiol 2002; 90:3F-6F.
22. Tostes RC, Nigro D, Fortes ZB, Carvalho MH. Effects of estrogen on the vascular system. Braz J Med Biol Res 2003; 36:1143-1158.
23. Rodriguez J, Garcia de Boto MJ, Hidalgo A. Mechanisms involved in the relaxant effect of estrogens on rat aorta strips. Life Sci 1996; 58:607-615.
24. Kelly MJ, Wagner El. Estrogen modulation of G-protein coupled receptors. Trends Endocrinol Metab 1999; 10:369-374.
25. Picotto G, Massheimer V, Boland R. Acute stimulation of intestinal cell calcium influx induced by 17 beta-estradiol via the cAMP messenger system. Mol Cell Endocrinol 1996; 119:129-134.
26. Perret S, Dockery P, Harvey BJ. 17beta-oestradiol stimulates capacitative ca2+ entry in human endometrial cells. Mol Cell Endocrinol 2001; 176:77-84.
27. Haynes MP, Li L, Sinha D, et al. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 2003; 278:2118-2123.
28. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87:677-682.
29. Chen ZP, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999; 443:285-289.
30. Li X-A, Titlow WB, Jackson BA, et al. High-density lipoprotein binding to scavenger receptor class B, type I activates endothelial nitric oxide synthase in a ceramide-dependent manner. J Biol Chem 2002; 277:11058-11063.
31. Kelly MJ, Levin ER. Rapid action of plasma membrane estrogen receptors. Trends Endocrinol Metab 2001; 12:152-156.
32. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001; 280:F193-F206.
33. Chambliss KL, Yuhanna IS, Mineo C, et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a function signaling module in caveolae. Circ Res 2000; 87:E44-E52.
34. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002; 23:665-686.
35. Chambliss KL, Yuhanna IS, Anderson RG, et al. ERbeta has nongenomic action in caveolae. Mol Endocrinol 2002; 16:938-946.
36. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the raloxifene use for the heart (RUTH) study. Am J Cardiol 2001; 88:392-395.
37. Gong MC, Wilson ME, Kelly T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 2003; 111:1579-1587. This study demonstrates that HDL action on endothelial cells involves delivery of estrogen to caveolae, mediated by a specific lipoprotein receptor. When this study is considered in light of Refs [16,17,33,35], it becomes clear that the overall effect and duration of estrogen action in a cell is dependent on a complex set of regulated interactions.
38. Kramer PR, Kramer SF, Guan G. 17 Beta-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages. Arthritis Rheum 2004; 50:1967-1975.
39. Kramer PR, Wray S. 17-Beta-estradiol regulates expression of genes that function in macrophage activation and cholesterol homeostasis. J Steroid Biochem 2002; 81:203-216.
40. Carruba G, D'Agostino P, Miele M, et al. Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells. J Cell Biochem 2003; 90:187-196.
41. Akoum A, Jolicoeur C, Boucher A. Estradiol amplifies interleukin-1- induced monocyte chemotactic protein-1 expression by ectopic endometrial cells of women with endometriosis. J Clin Endocrinol Metab 2000; 85:896-904.
42. Seli E, Kayisli UA, Selam B, et al. Estradiol suppresses vascular monocyte chemotactic protein-1 expression during early atherogenesis. Am J Obstet Gynecol 2002; 187:1544-1549.
43. Ahmed SA, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune disease: mechanisms of sex hormone action. Am J Pathol 1985; 121:531-551.
44. Mor G, Sapi E, Abrahams VM, et al. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol 2003; 170:114-122.
45. Katzenellenbogen BS, Sun J, Harrington WR, et al. Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann N Y Acad Sci 2001; 949:6-15.
46. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001; 93:1449-1457.
47. Nilsson S, Gustafsson JA. Biological role of estrogen and estrogen receptors. Crit Rev Biochem Mol Biol 2002; 37:1-18.
48. Barrett-Connor E, Ensrud KE, Harper K, et al. Post hoc analysis of data from the multiple outcomes of raloxifene evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003; 25:919-930. This is a clinical study that provides mechanistic information.
49. Arteaga E, Villaseca P, Bianchi M, et al. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 2003; 10:111-112.
50. Nickelsen T, Creatsas G, Rechberger T, et al. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 2001; 4:320-331.
51. Sugama D, Nakajima H, Maehara K, et al. Anti-atherosclerotic effects of tamoxifen in cholesterol-fed ovariectomized rabbits. Jpn Heart J 2002; 43:545-558.
52. Colacurci N, Manzella D, Fornaro F, et al. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003; 88:2135-2140.
53. Zoma WD, Baker RS, Kopernik G, et al. Differential effects of selective estrogen receptor modulators and estrogens on mammary blood flow in the ovine. Am J Obstet Gynecol 2002; 187:1555-1560.
54. Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol 2000; 182:521-528.
55. Wenger NK, Barrett-Connor E, Collins P, et al. Baseline characteristics of participants in the raloxifene use for the heart (RUTH) trial. Am J Cardiol 2002; 90:1204-1210.